A Part of the University of Maryland Medical Center

• Hematologic Malignancies Program

• Diagnosis and Treatment...
  • Multiple Myeloma
• Physicians and Staff
• Q&A with Dr. Maria Baer
• Patient Education...
• 
    Related Resources
• Clinical Trials
• Information for Patients

• Adult Acute Lymphoblastic Leukemia Treatment
• Adult Acute Myeloid Leukemia Treatment
• Adult Hodgkin Lymphoma Treatment
• Adult Non-Hodgkin Lymphoma Treatment
• AIDS-Related Lymphoma Treatment
• Childhood Acute Lymphoblastic Leukemia Treatment
• Childhood Acute Myeloid Leukemia Treatment
• Childhood Hodgkin Lymphoma Treatment
• Childhood Non-Hodgkin Lymphoma Treatment
• Chronic Lymphocytic Leukemia Treatment
• Chronic Myelogenous Leukemia Treatment
• Chronic Myeloproliferative Disorders Treatment
• Hairy Cell Leukemia Treatment
• Langerhans Cell Histiocytosis Treatment
• Myelodysplastic Syndromes Treatment
• Myelodysplastic/ Myeloproliferative Neoplasms Treatment
• Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment
• Primary CNS Lymphoma Treatment

Hematologic Malignancies

Diagnostic and Treatment Services

Patients with hematologic malignancies often have a complex array of medical issues. Our Program for Hematologic Malignancies brings together a team of specialists to provide patients with individualized treatment plans without duplicating services. Patients are evaluated by:

• Medical oncologists/hematologists
• Specialized nurses, nurse practitioners, and research nurses
• Radiation oncologists
• Pathologists
• Nutritionists
• Social workers

The Program for Hematologic Malignancies offers a comprehensive range of diagnostic and treatment services designed to provide patients with the most effective care possible. Services include:

• On-site specialized diagnostic and support services, including hematopathology, molecular diagnosis, immunophenotyping, special cell component therapy and pheresis, and infectious disease specialists
• Integrated programs with the Blood and Marrow Transplant Program
• Second opinions
• New therapies

We also treat benign hematology – bleeding disorders, red cell disorders, platelet abnormalities and white cell disorders.

A major goal of Hematologic Malignancies Program is to develop new curative approaches for leukemias, lymphomas and myelomas. For example:

1. We offer a number of NCI-funded Phase I and II innovative clinical trials of new drugs and novel drug combinations for patients with newly diagnosed or relapsed and/or refractory leukemias and myelodysplasia.
2. We use novel immunotherapy approaches to treat Chronic Myelogenous Leukemia (CML), lymphoma and multiple myeloma.
3. We offer new molecularly-targeted drugs for multiple myeloma.

If you would like to make an appointment, or if you are a physician with a patient who would benefit from the expertise and treatment we offer, please call us at 1-800-888-8823

This page was last updated on: May 19, 2009.

---

For More Information

• Have questions about hematologic malignancies? Ask our Team of Experts.
• Patient Handbook (PDF)

Please rate the quality of this article. Do you find this article to be helpful / informative?                Poor                                       Excellent Do you have any brief comments on this page: (up to 255 characters) Note: If you have a question, please contact Ask the Expert.

Email this Page                                                                     Print this Page